November 19, 2019
CHECK OUT OUR NOVEMBER ISSUE
View the
latest issue
online.
Combination therapy addressed in amended OAB guideline
In this interview, Sandip Vasavada, MD, discusses the rationale behind the recent amendment to the AUA/SUFU guideline for overactive bladder, the role of OAB drugs in the treatment of nocturia, and treatment of refractory OAB.
Read the interview
As 2020 approaches, it’s time to review your financial strategies
"This time of year presents the perfect opportunity to review and possibly adjust your financial planning strategies," writes Jeff Witz, CFP.
Get his advice
SURVEY
Is DRE still a relevant tool in the management of prostate cancer?
MORE FROM
UROLOGY TIMES
Urology groups: 340B program reform needed
Why private equity is right for some, not all, practices